Clinical Pearls and Closing Thoughts on NSCLC Treatment Landscape
Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.
Emerging Targets in Non–Small Cell Lung Cancer
Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.
Treating MET Exon 14 NSCLC
The focus turns to therapeutic strategies for treating MET exon 14 non–small cell lung cancer.
Approach to Treating Patients with NSCLC and RET Fusions
Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.
Treatment of NTRK Fusions in NSCLC
Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.
Choosing Between ALK Inhibitors in the Treatment of NSCLC
The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.
Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements
Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.
Is There a Role for Immunotherapy in Patients with KRAS G12C-Mutant NSCLC and STK11 or KEAP1 Co-Mutations?
Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.
Adagrasib for Patients with KRAS G12C–Mutant NSCLC
Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.
Sotorasib in the Treatment of KRAS G12C–Mutant NSCLC
Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.
NSCLC With Uncommon EGFR Mutations: First-Generation EGFR TKIs and Role of Immunotherapy
Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.
Choosing Treatments for Patients with NSCLC with Uncommon EGFR Mutations
Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.
Treatment Options for Patients with NSCLC with EGFR Mutations
Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.
Strategies to Improve Biomarker Testing in NSCLC
Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.
Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC
Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.
NSCLC: Biomarker Testing Strategies and Turnaround Time
Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.
Liquid vs Tissue Biopsies in NSCLC
Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.
Biomarker Testing in Non-Small Cell Lung Cancer
A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.
Dr Raez on the Effect of the NADIM II Trial on the Neoadjuvant Treatment Paradigm in NSCLC
Luis E. Raez, MD, discusses how findings from the phase 2 NADIM II trial inform the neoadjuvant treatment paradigm in non–small cell lung cancer.
Dr. Raez on the Clinical Implications of the KEYNOTE-024 Trial in NSCLC
Luis E. Raez, MD, discusses the clinical implications of the phase 3 KEYNOTE-024 trial in non–small cell lung cancer.
Dr. Raez on the Impact of PD-L1 Status on Immunotherapy Outcomes in NSCLC
Luis E. Raez, MD, discusses the impact of PD-L1 status on immunotherapy outcomes for patients with non–small cell lung cancer.
Dr. Raez on the Potential Utility of Cemiplimab in NSCLC
Luis E. Raez, MD, discusses the potential utility of cemiplimab-rwlc in non–small cell lung cancer.
Dr. Raez on Safety Measures to Combat Challenges of COVID-19 in Lung Cancer
Luis E. Raez, MD, discusses the safety measures that have been put in place at Memorial Cancer Institute in response to the coronavirus disease 2019 (COVID-19) in lung cancer.
Dr. Raez on State of Lung Cancer Treatment in Light of COVID-19
Luis E. Raez, MD, discusses how the COVID-19 pandemic has impacted the treatment of patients with lung cancer.
Dr. Raez on the Benefits of Liquid Biopsies in Newly Diagnosed Lung Cancer
Luis E. Raez, MD, discusses the role of liquid biopsies in newly diagnosed patients with lung cancer.
Dr. Raez on the KEYNOTE-407 Trial in Squamous NSCLC
Luis E. Raez, MD, discusses the impact of the KEYNOTE-407 trial in squamous non–small cell lung cancer.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512